FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106573575> ?p ?o ?g. }

• W2106573575 endingPage "1411" @default.
• W2106573575 startingPage "1405" @default.
• W2106573575 abstract "Dexamethasone, plus a 5-HT3 receptor antagonist and an NK-1 receptor antagonist are recommended for controlling the chemotherapy-induced nausea and vomiting (CINV) of highly emetogenic chemotherapy. Several days of dexamethasone are effective for CINV; however, dexamethasone also has side effects. The purpose of this trial was to investigate whether the use of a second-generation 5-HT3 receptor antagonist and an NK-1 receptor antagonist could allow a reduced dose of dexamethasone for breast cancer patients receiving highly emetogenic chemotherapy.Eighty breast cancer patients who received an anthracycline-cyclophosphamide combination regimen were enrolled. The patients were randomized to arm A (dexamethasone days 1-3) and arm B (dexamethasone day 1). The primary endpoint was complete response (CR) (no emetic episodes and no rescue medication) during the overall phase (days 1-5). The secondary endpoints were the CR during the delayed phase (days 2-5), complete control (CC) (no emetic episodes, no rescue medication, and no more than mild nausea) during the overall phase, and the safety of this antiemetic therapy.There were no significant differences in the rates of CR and CC between arm A and B as follows: CR overall phase--arm A: 82.9%, 90% confidence interval [CI] 71.3-90.5% vs arm B: 82.1%, 90% CI 70.0-90.0%; p = 1.00; CR delayed phase--arm A: 87.8%, 90% CI 77.0-93.9% vs arm B: 94.9%, 90% CI 85.6-98.3%; p = 0.43; CC overall phase--arm A: 48.8%, 90% CI 36.4-61.3% vs arm B: 61.5%, 90% CI 48.4-73.2%; p = 0.27. There were very few adverse events and no severe adverse events associated with this antiemetic therapy.The results suggest that the antiemetic effect provided by dexamethasone administered for 3 days can be obtained by dexamethasone administered for 1 day." @default.
• W2106573575 created "2016-06-24" @default.
• W2106573575 creator A5002049972 @default.
• W2106573575 creator A5007874609 @default.
• W2106573575 creator A5017811687 @default.
• W2106573575 creator A5019725854 @default.
• W2106573575 creator A5021510795 @default.
• W2106573575 creator A5031944340 @default.
• W2106573575 creator A5033940341 @default.
• W2106573575 creator A5039457576 @default.
• W2106573575 creator A5049888460 @default.
• W2106573575 creator A5054577000 @default.
• W2106573575 creator A5061833051 @default.
• W2106573575 creator A5080589802 @default.
• W2106573575 date "2015-09-08" @default.
• W2106573575 modified "2023-10-16" @default.
• W2106573575 title "Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy" @default.
• W2106573575 cites W1502901901 @default.
• W2106573575 cites W1876492466 @default.
• W2106573575 cites W1967577450 @default.
• W2106573575 cites W1976163648 @default.
• W2106573575 cites W2012007321 @default.
• W2106573575 cites W2015639537 @default.
• W2106573575 cites W2020695269 @default.
• W2106573575 cites W2023045600 @default.
• W2106573575 cites W2035395673 @default.
• W2106573575 cites W2072532597 @default.
• W2106573575 cites W2076161482 @default.
• W2106573575 cites W2087393401 @default.
• W2106573575 cites W2107985230 @default.
• W2106573575 cites W2118261787 @default.
• W2106573575 cites W2120978512 @default.
• W2106573575 cites W2141342797 @default.
• W2106573575 cites W2151039173 @default.
• W2106573575 cites W2155726820 @default.
• W2106573575 cites W2158036326 @default.
• W2106573575 cites W2171896543 @default.
• W2106573575 doi "https://doi.org/10.1007/s00520-015-2905-4" @default.
• W2106573575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4729792" @default.
• W2106573575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26349772" @default.
• W2106573575 hasPublicationYear "2015" @default.
• W2106573575 type Work @default.
• W2106573575 sameAs 2106573575 @default.
• W2106573575 citedByCount "12" @default.
• W2106573575 countsByYear W21065735752016 @default.
• W2106573575 countsByYear W21065735752017 @default.
• W2106573575 countsByYear W21065735752019 @default.
• W2106573575 countsByYear W21065735752020 @default.
• W2106573575 countsByYear W21065735752021 @default.
• W2106573575 countsByYear W21065735752022 @default.
• W2106573575 crossrefType "journal-article" @default.
• W2106573575 hasAuthorship W2106573575A5002049972 @default.
• W2106573575 hasAuthorship W2106573575A5007874609 @default.
• W2106573575 hasAuthorship W2106573575A5017811687 @default.
• W2106573575 hasAuthorship W2106573575A5019725854 @default.
• W2106573575 hasAuthorship W2106573575A5021510795 @default.
• W2106573575 hasAuthorship W2106573575A5031944340 @default.
• W2106573575 hasAuthorship W2106573575A5033940341 @default.
• W2106573575 hasAuthorship W2106573575A5039457576 @default.
• W2106573575 hasAuthorship W2106573575A5049888460 @default.
• W2106573575 hasAuthorship W2106573575A5054577000 @default.
• W2106573575 hasAuthorship W2106573575A5061833051 @default.
• W2106573575 hasAuthorship W2106573575A5080589802 @default.
• W2106573575 hasBestOaLocation W21065735751 @default.
• W2106573575 hasConcept C118303440 @default.
• W2106573575 hasConcept C121608353 @default.
• W2106573575 hasConcept C126322002 @default.
• W2106573575 hasConcept C168563851 @default.
• W2106573575 hasConcept C170493617 @default.
• W2106573575 hasConcept C202871150 @default.
• W2106573575 hasConcept C203092338 @default.
• W2106573575 hasConcept C2776533618 @default.
• W2106573575 hasConcept C2776712918 @default.
• W2106573575 hasConcept C2776802502 @default.
• W2106573575 hasConcept C2777170512 @default.
• W2106573575 hasConcept C2779924295 @default.
• W2106573575 hasConcept C2780401358 @default.
• W2106573575 hasConcept C2780574406 @default.
• W2106573575 hasConcept C2780580376 @default.
• W2106573575 hasConcept C2780852908 @default.
• W2106573575 hasConcept C2780884295 @default.
• W2106573575 hasConcept C2781413609 @default.
• W2106573575 hasConcept C42219234 @default.
• W2106573575 hasConcept C530470458 @default.
• W2106573575 hasConcept C71924100 @default.
• W2106573575 hasConcept C90924648 @default.
• W2106573575 hasConceptScore W2106573575C118303440 @default.
• W2106573575 hasConceptScore W2106573575C121608353 @default.
• W2106573575 hasConceptScore W2106573575C126322002 @default.
• W2106573575 hasConceptScore W2106573575C168563851 @default.
• W2106573575 hasConceptScore W2106573575C170493617 @default.
• W2106573575 hasConceptScore W2106573575C202871150 @default.
• W2106573575 hasConceptScore W2106573575C203092338 @default.
• W2106573575 hasConceptScore W2106573575C2776533618 @default.
• W2106573575 hasConceptScore W2106573575C2776712918 @default.
• W2106573575 hasConceptScore W2106573575C2776802502 @default.
• W2106573575 hasConceptScore W2106573575C2777170512 @default.
• W2106573575 hasConceptScore W2106573575C2779924295 @default.

• next